DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1440 surveillance study in HIV-infected patients. Chest, 2003,
123:1983–1987.
Olliaro PL, Guerin PJ, Gerstl S, et al. Treatment options for visceral
leishmaniasis: A systematic review of clinical studies
done in India, 1980–2004. Lancet Infect Dis, 2005, 5:763–774.
Paulos C, Paredes J, Vasquez I, et al. Pharmacokinetics of a nitrofuran
compound, nifurtimox, in healthy volunteers. Int J Clin
Pharmacol Ther Toxicol, 1989, 27:454–457.
Pepin J, Mpia B. Trypanosomiasis relapse after melarsoprol therapy,
Democratic Republic of Congo, 1982–2001. Emerg Infect
Dis, 2005, 11:921–927.
Pepin J, Mpia B. Randomized controlled trial of three regimens
of melarsoprol in the treatment of Trypanosoma brucei gambiense
trypanosomiasis. Trans R Soc Trop Med Hyg, 2006,
100:437–441.
Pink R, Hudson A, Mouries MA, Bendig M. Opportunities and
challenges in antiparasitic drug discovery. Nat Rev Drug
Discov, 2005, 4:727–740.
Podolsky DK. Inflammatory bowel disease. N Engl J Med, 2002,
347:417–429.
Priotto G, Fogg C, Balasegaram M, et al. Three drug combinations
for late-stage Trypanosoma brucei gambiense sleeping
sickness: A randomized clinical trial in Uganda. PLoS Clin
Trials, 2006, 1:e39.
Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine
combination therapy for seond-stage African Trypanosoma
brucei gambiense trypanosomiasis: a multi-centre, randomized,
phase III, non-inferiority trial. Lancet, 2009, 374:56–64.
Priotto G, Pinoges L, Fursa IB, et al. Safety and effectiveness of
first line eflornithine for Trypanosoma brucei gambiense
sleeping sickness in Sudan: Cohort study. BMJ, 2008,
336:705–708.
Raether W, Hänel H. Nitroheterocyclic drugs with broadspectrum
activity. Parasitol Res, 2003, 90(suppl):19–39.
Ramirez NE, Ward LA, Sreevatsan, S. A review of the biology
and epidemiology of cryptosporidiosis in humans and animals.
Microbes Infect, 2004, 6:773–785.
Robays J, Nyamowala G, Sese C, et al. High failure rates of
melarsoprol for sleeping sickness, Democratic Republic of
Congo. Emerg Infect Dis, 2008b, 14:966–967.
Robays J, Raguenaud ME, Josenando T, Boelaert M.
Eflornithine is a cost-effective alternative to melarsoprol for
the treatment of second-stage human West African trypanosomiasis
in Caxito, Angola. Trop Med Int Health, 2008a,
13:265–271.
Romero-Cabello R, Guerrero LR, Munoz-Garcia MR, Geyne-
Cruz A. Nitazoxanide for the treatment of intestinal protozoan
and helminthic infections in Mexico. Trans R Soc Trop Med
Hyg, 1997, 91:701–703.
Rossignol J. Nitazoxanide in the treatment of acquired immune
deficiency syndrome-related cryptosporidiosis: results of the
United States compassionate use program in 365 patients.
Aliment Pharmacol Ther, 2006, 24:887–894.
Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused
by Cryptosporidium parvum: A prospective, randomized,
double-blind, placebo-controlled study of nitazoxanide. J Infect
Dis, 2001, 184:103–106.
Rossignol JF, Keeffe EB. Thiazolides: A new class of drugs for
the treatment of chronic hepatitis B and C. Future Microbiol,
2008, 3:539–545.
SECTION VII
CHEMOTHERAPY OF MICROBIAL DISEASES
Rossignol JF, Maisonneuve H. Nitazoxanide in the treatment of
Taenia saginata and Hymenolepis nana infections. Am J Trop
Med Hyg, 1984, 33:511–512.
Sanderson L, Dogruel M, Rodgers J, et al. The blood-brain barrier
significantly limits eflornithine entry into Trypanosoma
brucei brucei infected mouse brain. J Neurochem, 2008,
107:1136–1146.
Schmid C, Richer M, Bilenge CM, et al. Effectiveness of a 10-
day melarsoprol schedule for the treatment of late-stage
human African trypanosomiasis: Confirmation from a multinational
study (IMPAMEL II). J Infect Dis, 2005, 191:
1922–1931.
Sears CL, Kirkpatrick BD. Is nitazoxanide an effective treatment
for patients with acquired immune deficiency syndromerelated
cryptosporidiosis? Nature Clin Pract, 2007, 4:
136–137.
Seifert K, Perez-Victoria FJ, Stettler M, et al. Inactivation of the
miltefosine transporter, LdMT, causes miltefosine resistance
that is conferred to the amastigote stage of Leishmania donovani
and persists in vivo. Int J Antimicrob Agents, 2007,
30:229–235.
Smego RA Jr, Nagar S, Maloba B, Popara M. A meta-analysis of
salvage therapy for Pneumocystis carinii pneumonia. Arch
Intern Med, 2001, 161:1529–1533.
Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant
vaginal trichomoniasis. Clin Infect Dis, 2001,
33:1341–1346.
Soto J, Berman J. Treatment of New World cutaneous leishmaniasis
with miltefosine. Trans R Soc Trop Med Hyg, 2006,
100(suppl 1):S34–40.
Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal
leishmaniasis with miltefosine. Clin Infect Dis, 2007,
44:350–356.
Stanley SL Jr. Amoebiasis. Lancet, 2003, 361:1025–1034.
Stuart K, Brun R, Croft S, et al. Kinetoplastids: Related protozoan
pathogens, different diseases. J Clin Invest, 2008, 118:
1301–1310.
Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin
for visceral leishmaniasis in India. N Engl J Med, 2007,
356:2571–2581.
Sundar S, Rai M, Chakravarty J, et al. New treatment approach
in Indian visceral leishmaniasis: Single-dose liposomal
amphotericin B followed by short-course oral miltefosine. Clin
Infect Dis, 2008, 47:1000–1006.
Tarleton RL. Chagas disease: A role for autoimmunity? Trends
Parasitol, 2003, 19:447–451.
Tarleton RL, Reithinger R, Urbina JA, et al. The challenges of
Chagas Disease—grim outlook or glimmer of hope. PLoS
Med, 2007, 4:e332.
Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J
Med, 2004, 350:2487–2498.
Upcroft JA, Campbell RW, Benakli K, et al. Efficacy of new
5-nitroimidazoles against metronidazole-susceptible and -resistant
Giardia, Trichomonas, and Entamoeba spp. Antimicrob Agents
Chemother, 1999, 43:73–76.
Upcroft JA, Upcroft P. Keto-acid oxidoreductases in the anaerobic
protozoa. J Eukaryot Microbiol, 1999, 46:447–449.
Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance
in the anaerobic protozoa. Clin Microbiol Rev, 2001,
14:150–164.